UMN Pharma, a clinical-stage vaccine focused biopharmaceutical company, and Timo Vesikari, M.D. and Vesna Blazevic, Ph.D. of the University of Tampere Vaccine Research Center, announced today that they have entered into a licensing agreement that provides UMN Pharma with exclusive worldwide rights to develop and commercialize a novel norovirus VLP + rotavirus VP6 non-live injectable adjuvant-free vaccine candidate developed by a research group led by Dr. Vesikari and Dr. Blazevic for the prevention of two major causative agents of acute gastroenteritis in children.

 The University of Tampere Vaccine Research Center